Clinical Trial

Tauroursodeoxycholic Acid (TUDCA) Plus Camrelizumab and Regorafenib in Hepatocellular Carcinoma Previously Treated With Anti-PD1/PD-L1 and Bevacizumab

Study acronym: LEAF-02
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
To evaluate the efficacy and safety of Tauroursodeoxycholic Acid (TUDCA) plus Camrelizumab and Regorafenib for patients with advanced hepatocellular carcinoma (HCC) who have progressed on prior systemic treatment with Anti-PD1/PD-L1 plus bevacizumab combination.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-07-27; most recent amendment 2025-08-14.
Status change: Not Yet Recruiting → Recruiting 2025-08-10
Trial Details
NCT Number NCT07100392
Lead Sponsor Fudan University
Conditions Hepatocellular Carcinoma (HCC)
Enrollment 141 participants
Start Date 2025-08-14
Primary Completion 2027-08-01 (estimated)
Study Completion 2028-08-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-17